Results 21 to 30 of about 1,901 (143)

Severe hypophosphataemic osteomalacia related to low-dose adefovir dipivoxil therapy in a hepatitis B virus patient

Endokrynologia Polska, 2021
Not required for Clinical Vignette.
Xiushuai Dong, Xi Chen, Yaoyao Tian, Jinghua Wang   +3 more
doaj   +1 more source

Development and Validation of RP-HPLC Method for the Determination of Adefovir Dipivoxil in Bulk and in Pharmaceutical Formulation

E-Journal of Chemistry, 2009
A rapid and sensitive RP-HPLC method with UV detection (262 nm) for routine analysis of adefovir dipivoxil in bulk and in pharmaceutical formulation was developed.
Zaheer Ahmed, B. Gopinath, A. Sathish Kumar Shetty, B. K. Sridhar   +3 more
doaj   +1 more source

Hypophosphatemia Due to Adefovir Treatment [PDF]

Mediterranean Journal of Infection, Microbes and Antimicrobials, 2012
Adefovir dipivoxil is an orally effective prodrug excreted unchanged in urine by glomerular filtration and tubular secretion. While it effectively suppresses hepatitis B virus replication, it may cause nephrotoxicity characterized by severe ...
Nazlım AKTUĞ DEMİR, Servet KÖLGELİER, Serap ÖZÇİMEN, Selçuk AKSÖZ, Ahmet Çağkan İNKAYA   +4 more
doaj  

Adefovir dipivoxil-induced development of osteomalacia and Fanconi syndrome during the treatment of hepatitis B virus (HBV)-related cirrhosis

Clinical Management Issues, 2014
Adefovir dipivoxil is a nucleotide analog reverse transcriptase inhibitor used to treat adult patients affected by HBeAg-positive and HBeAg-negative chronic hepatitis B and with clinical evidence of lamivudine-resistant hepatitis B virus (HBV).
Orietta Staltari, Benedetto Caroleo, Andzelika Michniewicz, Giovambattista De Sarro, Franco Perticone, Luca Gallelli   +5 more
doaj   +1 more source

Spectrophotometric Determination of Adefovir Dipivoxil in bulk and Pharmaceutical Formulation

E-Journal of Chemistry, 2008
Two selective and sensitive spectrophotometric methods have been developed for the estimation of adefovir dipivoxil in bulk and pharmaceutical preparations.
Zaheer Ahmed, Y. N. Manohara, K. P. Channabasawaraj, Manish Majumdar   +3 more
doaj   +1 more source

Milestones in the discovery of antiviral agents: nucleosides and nucleotides

Acta Pharmaceutica Sinica B, 2012
In this review article, a number of milestones in the antiviral research field on nucleosides and nucleotides are reviewed in which the author played a significant part, especially in the initial stages of their development.
Erik de Clercq
doaj   +1 more source

Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus [PDF]

Clinical and Molecular Hepatology, 2014
Background/AimsAdefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistant hepatitis B virus (HBV). The aim of this study was to determine the long-term clinical outcomes after ADV rescue therapy in decompensated ...
Hyun Young Woo, Jong Young Choi, Seung Kew Yoon, Dong Jin Suh, Seung Woon Paik, Kwang Hyub Han, Soon Ho Um, Byung Ik Kim, Heon Ju Lee, Mong Cho, Chun Kyon Lee, Dong Joon Kim, Jae Seok Hwang   +12 more
doaj   +1 more source

Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV

American Journal of Reproductive Immunology, Volume 95, Issue 5, May 2026.
ABSTRACT Background Antiretroviral therapy (ART) suppresses HIV replication and protects people living with HIV (PLWH) from progressing to AIDS. However, despite ART, many PLWH experience chronic immune activation, which contributes to premature aging and non‐AIDS‐related comorbidities. One reason for this chronic immune activation (CIA) is HIV and its
Florian Hladik, Sean M. Hughes, Claire N. Levy, Rachel L. Creighton, Romel Mackelprang, Germán G. Gornalusse   +5 more
wiley   +1 more source

Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections

Viruses, 2010
While 25 compounds have been formally licensed for the treatment of HIV infection (AIDS), only seven licensed products are currently available for the treatment of chronic hepatitis B virus (HBV) infection: interferon-α, pegylated interferon-α ...
Erik De Clercq, Geoffrey Férir, Suzanne Kaptein, Johan Neyts   +3 more
doaj   +1 more source

Evidence that C/EBP-β LAP Increases Fat Metabolism and Protects Against Diet-Induced Obesity in Response to mTOR Inhibition

Frontiers in Aging, 2021
Aging and obesity are common risk factors for numerous chronic pathologies, and the compounding effects of old age and increased adiposity pose a serious threat to public health.
Alessandro Bitto, Nicole Tatom, Thomas Krivak, Peter Grotz, Matt Kaeberlein   +4 more
doaj   +1 more source